Akums Drugs Convenes Board Meeting To Approve Q2 Financial Results
NiveshIQ
NSE: AKUMS · Healthcare
Akums Drugs and Pharmaceuticals Ltd.
₹733.15▲ ₹1.45 (+0.20%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on AKUMS. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Akums Drugs and Pharmaceuticals Ltd.
Akums Drugs and Pharmaceuticals Limited (AKUMS) is a diversified Indian pharmaceutical company that manufactures and markets a broad portfolio of drugs, ayurvedic and nutraceutical products, active pharmaceutical ingredients (APIs), excipients, and contract development and manufacturing services (CDMO). In FY27 Q2, the company achieved a 31.9% year‑on‑year revenue increase to ₹4,504 crore and an impressive 106.1% rise in EBITDA, driven largely by CDMO contracts and a ₹560 million acquisition that expanded its manufacturing footprint. Net income for the quarter rose to ₹292 crore, reflecting higher margins and cost efficiencies. Akums’ competitive edge lies in its multi‑segment product mix and strong presence in both domestic and international markets, supported by a robust R&D pipeline. Th
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹4,178 Cr +14.30% | ₹4,118 Cr -1.40% | ₹4,359 Cr +5.85% |
| EBITDA Margin | 2.94% | 11.28% | 11.98% |
| Net Profit | ₹2.00 Cr -98.00% | ₹338.18 Cr +17100.00% | ₹255.19 Cr -24.54% |
| EPS | ₹-0.29 | ₹22.60 | ₹16.67 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
AKUMS: CDMO-led growth drove Q2 revenue up 31.9% and EBITDA up 106.1% YoY
Akums reports 32% revenue growth and 106% EBITDA growth in Q2 FY27
🔒
+ 3 more stories about Akums Drugs and Pharmaceuticals Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹1, 342 Cr, PAT ₹113 Cr, EPS ₹7.37, EBITDA margin 14.5%. Growth context: revenue YoY +31.9%, PAT YoY +176.7%, revenue QoQ +15.1%, PAT QoQ +12.8%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement and R&D investments and te...
FY26 (last completed FY): revenue ₹4, 359 Cr, PAT ₹255 Cr, EBITDA margin 12.0%, EPS ₹16.67. Year-on-year: revenue YoY +5...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for AKUMS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track AKUMS alongside your other holdings
Unlock full AKUMS research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Akums Drugs and Pharmaceuticals Ltd.?
NiveshIQ detects active intelligence signals for Akums Drugs and Pharmaceuticals Ltd. (AKUMS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Akums Drugs and Pharmaceuticals Ltd.?
Akums Drugs and Pharmaceuticals Ltd. operates in the Healthcare sector with a market capitalisation of ₹786,868.1L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.